Featured content in this Issue:
- Public and Industry Respond to DEA’s Renewed Plan to Place DOI and DOC in Schedule I
- Updates on State Psychedelics Programs
- Fourth Time Lucky for California Psychedelic Policy Reform?
- Backlash in Oregon; Updated Oregon Psilocybin Services Rules
- Colorado Natural Medicine Updates
- Mass. Legislature Considers Legal Psychedelics
- TARA Mind Scores $8M Seed Round
- No New Psychiatric Drugs for Europeans in 2023
- Hallucinogen-Associated ER Visits
Companies, organisations and drug candidates mentioned in this Bulletin include: atai Life Sciences, TARA Mind, GH Research, Cybin, Psilera, Incannex.
This content is for Pα+ Subscribers
This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
